FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 332:1004-1014 April 13, 1995 Number 15 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article PubMed Citation

The taxanes are an important new class of anticancer agents that exert their cytotoxic effects through a unique mechanism. Paclitaxel (Taxol), the first taxane in clinical trials, is active against a broad range of cancers that are generally considered to be refractory to conventional chemotherapy. This has led to the regulatory approval of paclitaxel in the United States and many other countries for use in the palliative therapy of patients with ovarian and breast cancers resistant to chemotherapy. The challenge now is to develop strategies using paclitaxel in the initial therapy of cancers in which cure or improved survival may . . . [Full Text of this Article]

Mechanisms of Action and Resistance

Toxicity

Hypersensitivity Reactions

Hematologic Toxicity

Neurotoxicity

Cardiac Effects

Miscellaneous Toxic Effects

Clinical Pharmacology

Antitumor Activity

Ovarian Cancer

Breast Cancer

Lung Cancer

Head and Neck Cancer

Other Tumor Types

Future Directions

Source Information

From the Divisions of Pharmacology and Experimental Therapeutics (E.K.R.) and Medical Oncology (R.C.D.), Oncology Center, Johns Hopkins University School of Medicine, Baltimore.

Address reprint requests to Dr. Rowinsky at the Johns Hopkins Oncology Center, Division of Pharmacology and Experimental Therapeutics, 1-121, 600 N. Wolfe St., Baltimore, MD 21287-8934.

References

This article has been cited by other articles:

• Casini, S., Tan, H. L., Demirayak, I., Remme, C. A., Amin, A. S., Scicluna, B. P., Chatyan, H., Ruijter, J. M., Bezzina, C. R., van Ginneken, A. C.G., Veldkamp, M. W. (2009). Tubulin polymerization modifies cardiac sodium channel expression and gating. Cardiovasc Res 0: cvp352v2-cvp352 [Abstract] [Full Text]  
• Silvestri, D., Cristallini, C., Gagliardi, M., Barbani, N., D'Acunto, M., Ciardelli, G., Giusti, P. (2009). Acrylic Copolymers as Candidates for Drug-Eluting Coating of Vascular Stents. J Biomater Appl 24: 353-383 [Abstract]  
• KUWATA, M., YOSHIZAWA, K., MATSUMURA, M., TAKAHASHI, K., TSUBURA, A. (2009). Ocular Toxicity Caused by Paclitaxel in Neonatal Sprague-Dawley Rats. In Vivo 23: 555-560 [Abstract] [Full Text]  
• Ly, V. T., Caceres-Cortes, J., Zhang, D., Humphreys, W. G., Ekhato, I. V., Everett, D., Comezoglu, S. N. (2009). Metabolism and Excretion of an Oral Taxane Analog, [14C]3'-tert-Butyl-3'-N-tert-butyloxycarbonyl-4-deacetyl-3'-dephenyl-3'-N-debenzoyl-4-O-methoxy-paclitaxel (BMS-275183), in Rats and Dogs. Drug Metab. Dispos. 37: 1115-1128 [Abstract] [Full Text]  
• SHIMADA, T., UEDA, M., JINNO, H., CHIBA, N., WADA, M., WATANABE, J., ISHIHARA, K., KITAGAWA, Y. (2009). Development of Targeted Therapy with Paclitaxel Incorporated into EGF-conjugated Nanoparticles. Anticancer Res 29: 1009-1014 [Abstract] [Full Text]  
• Aoki, D., Oda, Y., Hattori, S., Taguchi, K.-i., Ohishi, Y., Basaki, Y., Oie, S., Suzuki, N., Kono, S., Tsuneyoshi, M., Ono, M., Yanagawa, T., Kuwano, M. (2009). Overexpression of Class III {beta}-Tubulin Predicts Good Response to Taxane-Based Chemotherapy in Ovarian Clear Cell Adenocarcinoma. Clin. Cancer Res. 15: 1473-1480 [Abstract] [Full Text]  
• CHARPIDOU, A. G., GKIOZOS, I., TSIMPOUKIS, S., APOSTOLAKI, D., DILANA, K. D., KARAPANAGIOTOU, E. M., SYRIGOS, K. N. (2009). Therapy-induced Toxicity of the Lungs: An Overview. Anticancer Res 29: 631-639 [Abstract] [Full Text]  
• XU, R., SATO, N., YANAI, K., AKIYOSHI, T., NAGAI, S., WADA, J., KOGA, K., MIBU, R., NAKAMURA, M., KATANO, M. (2009). Enhancement of Paclitaxel-induced Apoptosis by Inhibition of Mitogen-activated Protein Kinase Pathway in Colon Cancer Cells. Anticancer Res 29: 261-270 [Abstract] [Full Text]  
• Ostovan, M. A, Mollazadeh, R., Kojuri, J., Mirabadi, M. (2008). Experience with Paclitaxel-Eluting Infinnium Coronary Stents. Asian Cardiovasc. Thorac. Ann. 16: 454-458 [Abstract] [Full Text]  
• Matsumura, Y. (2008). Polymeric Micellar Delivery Systems in Oncology. Jpn J Clin Oncol 38: 793-802 [Abstract] [Full Text]  
• Penel, N., Bui, B. N., Bay, J.-O., Cupissol, D., Ray-Coquard, I., Piperno-Neumann, S., Kerbrat, P., Fournier, C., Taieb, S., Jimenez, M., Isambert, N., Peyrade, F., Chevreau, C., Bompas, E., Brain, E. G.C., Blay, J.-Y. (2008). Phase II Trial of Weekly Paclitaxel for Unresectable Angiosarcoma: The ANGIOTAX Study. JCO 26: 5269-5274 [Abstract] [Full Text]  
• Johnatty, S. E., Beesley, J., Paul, J., Fereday, S., Spurdle, A. B., Webb, P. M., Byth, K., Marsh, S., McLeod, H., AOCS Study Group, , Harnett, P. R., Brown, R., deFazio, A., Chenevix-Trench, G. (2008). ABCB1 (MDR 1) Polymorphisms and Progression-Free Survival among Women with Ovarian Cancer following Paclitaxel/Carboplatin Chemotherapy. Clin. Cancer Res. 14: 5594-5601 [Abstract] [Full Text]  
• Murillo, J. R. Jr, Cox, J. E., Oholendt, M. S. (2008). An Overview of Chemotherapy-Induced Peripheral Neuropathy. Journal of Pharmacy Practice 21: 138-145 [Abstract]  
• Hong, J. W., Lee, I.-H., Kwak, Y. H., Park, Y. T., Sung, H. C., Kwon, I. C., Chung, H. (2007). Efficacy and tissue distribution of DHP107, an oral paclitaxel formulation. Molecular Cancer Therapeutics 6: 3239-3247 [Abstract] [Full Text]  
• Kim, D. -W., Kim, S. -Y., Kim, H. -K., Kim, S. -W., Shin, S. W., Kim, J. S., Park, K., Lee, M. Y., Heo, D. S. (2007). Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer. Ann Oncol 18: 2009-2014 [Abstract] [Full Text]  
• Lee, B. H., Lee, J. E., Lee, K. W., Nam, H. Y., Jeon, H. J., Sung, Y. J., Kim, J. S., Lim, H. J., Park, J.-s., Ko, J. Y., Kim, D. J. (2007). Coating with paclitaxel improves graft survival in a porcine model of haemodialysis graft stenosis. Nephrol Dial Transplant 22: 2800-2804 [Abstract] [Full Text]  
• Park, S W, Lee, S H, Kim, C H, Jeon, G S, Hong, S J, Yi, J G, Jeon, H J (2007). Inhibition of pseudointimal hyperplasia in swine TIPS models: the efficacy of local delivery of paclitaxel using a perforated balloon catheter. Br. J. Radiol. 80: 702-707 [Abstract] [Full Text]  
• Broker, L. E., Veltkamp, S. A., Heath, E. I., Kuenen, B. C., Gall, H., Astier, L., Parker, S., Kayitalire, L., Lorusso, P. M., Schellens, J. H.M., Giaccone, G. (2007). A Phase I Safety and Pharmacologic Study of a Twice Weekly Dosing Regimen of the Oral Taxane BMS-275183. Clin. Cancer Res. 13: 3906-3912 [Abstract] [Full Text]  
• Mita, A. C., Olszanski, A. J., Walovitch, R. C., Perez, R. P., MacKay, K., Tuck, D. P., Simmons, C., Hammond, S., Mita, M. M., Beeram, M., Stone, A. J., Rowinsky, E. K., Lewis, L. D. (2007). Phase I and Pharmacokinetic Study of AI-850, A Novel Microparticle Hydrophobic Drug Delivery System for Paclitaxel. Clin. Cancer Res. 13: 3293-3301 [Abstract] [Full Text]  
• Ohe, Y, Ohashi, Y, Kubota, K, Tamura, T, Nakagawa, K, Negoro, S, Nishiwaki, Y, Saijo, N, Ariyoshi, Y, Fukuoka, M, For the FACS Cooperative Group, (2007). Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 18: 317-323 [Abstract] [Full Text]  
• Daghir, A., Anand, P., Gabra, H., Elliot, D. (2006). Drug-Induced Exacerbation of Glomus Tumour Pain. J Hand Surg Eur Vol 31: 692-692 [Full Text]  
• Frapolli, R., Marangon, E., Zaffaroni, M., Colombo, T., Falcioni, C., Bagnati, R., Simone, M., D'Incalci, M., Manzotti, C., Fontana, G., Morazzoni, P., Zucchetti, M. (2006). Pharmacokinetics and Metabolism in Mice of IDN 5390 (13-(N-Boc-3-i-butylisoserinoyl)-C-7,8-seco-10-deacetylbaccatin III), a New Oral C-seco-Taxane Derivative with Antiangiogenic Property Effective on Paclitaxel-Resistant Tumors. Drug Metab. Dispos. 34: 2028-2035 [Abstract] [Full Text]  
• Yokouchi, K., Numaguchi, Y., Kubota, R., Ishii, M., Imai, H., Murakami, R., Ogawa, Y., Kondo, T., Okumura, K., Ingber, D. E., Murohara, T. (2006). l-Caldesmon Regulates Proliferation and Migration of Vascular Smooth Muscle Cells and Inhibits Neointimal Formation After Angioplasty. Arterioscler. Thromb. Vasc. Bio. 26: 2231-2237 [Abstract] [Full Text]  
• Zhao, X., Wang, D., Zhao, Z., Xiao, Y., Sengupta, S., Xiao, Y., Zhang, R., Lauber, K., Wesselborg, S., Feng, L., Rose, T. M., Shen, Y., Zhang, J., Prestwich, G., Xu, Y. (2006). Caspase-3-dependent Activation of Calcium-independent Phospholipase A2 Enhances Cell Migration in Non-apoptotic Ovarian Cancer Cells. J. Biol. Chem. 281: 29357-29368 [Abstract] [Full Text]  
• Stahli, B. E., Camici, G. G., Steffel, J., Akhmedov, A., Shojaati, K., Graber, M., Luscher, T. F., Tanner, F. C. (2006). Paclitaxel Enhances Thrombin-Induced Endothelial Tissue Factor Expression via c-Jun Terminal NH2 Kinase Activation. Circ. Res. 99: 149-155 [Abstract] [Full Text]  
• Broker, L. E., de Vos, F. Y.F.L., van Groeningen, C. J., Kuenen, B. C., Gall, H. E., Woo, M. H., Voi, M., Gietema, J. A., de Vries, E. G.E., Giaccone, G. (2006). Phase I Trial with BMS-275183, a Novel Oral Taxane with Promising Antitumor Activity.. Clin. Cancer Res. 12: 1760-1767 [Abstract] [Full Text]  
• Dimopoulou, I., Bamias, A., Lyberopoulos, P., Dimopoulos, M. A. (2006). Pulmonary toxicity from novel antineoplastic agents. Ann Oncol 17: 372-379 [Abstract] [Full Text]  
• Desai, N., Trieu, V., Yao, Z., Louie, L., Ci, S., Yang, A., Tao, C., De, T., Beals, B., Dykes, D., Noker, P., Yao, R., Labao, E., Hawkins, M., Soon-Shiong, P. (2006). Increased Antitumor Activity, Intratumor Paclitaxel Concentrations, and Endothelial Cell Transport of Cremophor-Free, Albumin-Bound Paclitaxel, ABI-007, Compared with Cremophor-Based Paclitaxel. Clin. Cancer Res. 12: 1317-1324 [Abstract] [Full Text]  
• Azarbal, B., Currier, J. W. (2006). Allergic Reactions After the Implantation of Drug-Eluting Stents: Is it the Pill or the Polymer?. J Am Coll Cardiol 47: 182-183 [Full Text]  
• Nebeker, J. R., Virmani, R., Bennett, C. L., Hoffman, J. M., Samore, M. H., Alvarez, J., Davidson, C. J., McKoy, J. M., Raisch, D. W., Whisenant, B. K., Yarnold, P. R., Belknap, S. M., West, D. P., Gage, J. E., Morse, R. E., Gligoric, G., Davidson, L., Feldman, M. D. (2006). Hypersensitivity Cases Associated With Drug-Eluting Coronary Stents: A Review of Available Cases From the Research on Adverse Drug Events and Reports (RADAR) Project. J Am Coll Cardiol 47: 175-181 [Abstract] [Full Text]  
• Alvarez, W. Jr, Kapur, N. K. (2005). Drug Eluting Stent Technology: A Paradigm Shift in the Treatment and Prevention of Restenosis. Journal of Pharmacy Practice 18: 461-478 [Abstract]  
• Nyman, D. W., Campbell, K. J., Hersh, E., Long, K., Richardson, K., Trieu, V., Desai, N., Hawkins, M. J., Von Hoff, D. D. (2005). Phase I and Pharmacokinetics Trial of ABI-007, a Novel Nanoparticle Formulation of Paclitaxel in Patients With Advanced Nonhematologic Malignancies. JCO 23: 7785-7793 [Abstract] [Full Text]  
• Nawarskas, J. J., Osborn, L. A. (2005). Paclitaxel-eluting stents in coronary artery disease. Am J Health Syst Pharm 62: 2241-2251 [Abstract] [Full Text]  
• Safley, D. M, Marso, S. P (2005). Diabetes and percutaneous coronary intervention in the setting of an acute coronary syndrome. Diabetes and Vascular Disease Research 2: 128-135 [Abstract]  
• Divers, S. G., Spencer, S. A., Carey, D., Busby, E. M., Hyatt, M. D., Robert, F. (2005). Phase I/IIa Study of Cisplatin and Gemcitabine As Induction Chemotherapy Followed by Concurrent Chemoradiotherapy With Gemcitabine and Paclitaxel for Locally Advanced Non-Small-Cell Lung Cancer. JCO 23: 6664-6673 [Abstract] [Full Text]  
• Belani, C. P., Choy, H., Bonomi, P., Scott, C., Travis, P., Haluschak, J., Curran, W. J. Jr (2005). Combined Chemoradiotherapy Regimens of Paclitaxel and Carboplatin for Locally Advanced Non-Small-Cell Lung Cancer: A Randomized Phase II Locally Advanced Multi-Modality Protocol. JCO 23: 5883-5891 [Abstract] [Full Text]  
• Pace, A., Bove, L., Jandolo, B., Argyriou, A.A., Chroni, E., Koutras, A., Ellul, J., Papapetropoulos, S., Katsoulas, G., Iconomou, G., Kalofonos, H.P. (2005). Vitamin E for prophylaxis against chemotherapy-induced neuropathy: A randomized controlled trial. Neurology 65: 501-502 [Full Text]  
• Costa, M. A., Simon, D. I. (2005). Molecular Basis of Restenosis and Drug-Eluting Stents. Circulation 111: 2257-2273 [Full Text]  
• Chang, H. M., Kim, T. W., Ryu, B.-Y., Choi, S.-J., Park, Y. H., Lee, J. S., Kim, W. K., Kang, Y.-K. (2005). Phase II Study of Paclitaxel and Carboplatin in Advanced Gastric Cancer Previously Treated with 5-Fluorouracil and Platinum. Jpn J Clin Oncol 35: 251-255 [Abstract] [Full Text]  
• Garrett, C. R., Fishman, M. N., Rago, R. R., Williams, C. C., Dellaportas, A. M., Mahany, J. J., Lush, R. M., Dalton, W. S., Gollerkeri, A., Cohen, M. B., Sullivan, D. M. (2005). Phase I Study of a Novel Taxane BMS-188797 in Adult Patients with Solid Malignancies. Clin. Cancer Res. 11: 3335-3341 [Abstract] [Full Text]  
• Hofstetter, B., Vuong, V., Broggini-Tenzer, A., Bodis, S., Ciernik, I. F., Fabbro, D., Wartmann, M., Folkers, G., Pruschy, M. (2005). Patupilone Acts as Radiosensitizing Agent in Multidrug-Resistant Cancer Cells In vitro and In vivo. Clin. Cancer Res. 11: 1588-1596 [Abstract] [Full Text]  
• El Hilali, N., Rubio, N., Blanco, J. (2005). Different Effect of Paclitaxel on Primary Tumor Mass, Tumor Cell Contents, and Metastases for Four Experimental Human Prostate Tumors Expressing Luciferase. Clin. Cancer Res. 11: 1253-1258 [Abstract] [Full Text]  
• Han, G.-Z., Liu, Z.-J., Shimoi, K., Zhu, B. T. (2005). Synergism between the Anticancer Actions of 2-Methoxyestradiol and Microtubule-Disrupting Agents in Human Breast Cancer. Cancer Res. 65: 387-393 [Abstract] [Full Text]  
• Argyriou, A. A., Chroni, E., Koutras, A., Ellul, J., Papapetropoulos, S., Katsoulas, G., Iconomou, G., Kalofonos, H. P. (2005). Vitamin E for prophylaxis against chemotherapy-induced neuropathy: A randomized controlled trial. Neurology 64: 26-31 [Abstract] [Full Text]  
• Cannistra, S. A. (2004). Cancer of the Ovary. NEJM 351: 2519-2529 [Full Text]  
• Sabbatini, P., Aghajanian, C., Dizon, D., Anderson, S., Dupont, J., Brown, J. V., Peters, W. A., Jacobs, A., Mehdi, A., Rivkin, S., Eisenfeld, A. J., Spriggs, D. (2004). Phase II Study of CT-2103 in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma. JCO 22: 4523-4531 [Abstract] [Full Text]  
• Aapro, M. (2004). Granisetron: An Update on its Clinical Use in the Management of Nausea and Vomiting. The Oncologist 9: 673-686 [Abstract] [Full Text]  
• Kikuchi, J., Yamazaki, K., Kinoshita, I., Asahina, H., Imura, M., Kikuchi, E., Konishi, J., Shinagawa, N., Oki, H., Dosaka-Akita, H., Nishimura, M. (2004). Phase I Trial of Carboplatin and Weekly Paclitaxel in Patients With Advanced Non-small-cell Lung Cancer. Jpn J Clin Oncol 34: 505-509 [Abstract] [Full Text]  
• Lee, D.-k., Kim, Y. H., Kim, J.-S., Seol, W. (2004). Induction and characterization of taxol-resistance phenotypes with a transiently expressed artificial transcriptional activator library. Nucleic Acids Res 32: e116-e116 [Abstract] [Full Text]  
• Gapud, E. J., Bai, R., Ghosh, A. K., Hamel, E. (2004). Laulimalide and Paclitaxel: A Comparison of Their Effects on Tubulin Assembly and Their Synergistic Action When Present Simultaneously. Mol. Pharmacol. 66: 113-121 [Abstract] [Full Text]  
• Kim, T.-Y., Kim, D.-W., Chung, J.-Y., Shin, S. G., Kim, S.-C., Heo, D. S., Kim, N. K., Bang, Y.-J. (2004). Phase I and Pharmacokinetic Study of Genexol-PM, a Cremophor-Free, Polymeric Micelle-Formulated Paclitaxel, in Patients with Advanced Malignancies. Clin. Cancer Res. 10: 3708-3716 [Abstract] [Full Text]  
• Kirson, E. D., Gurvich, Z., Schneiderman, R., Dekel, E., Itzhaki, A., Wasserman, Y., Schatzberger, R., Palti, Y. (2004). Disruption of Cancer Cell Replication by Alternating Electric Fields. Cancer Res. 64: 3288-3295 [Abstract] [Full Text]  
• Ling, X., Bernacki, R. J., Brattain, M. G., Li, F. (2004). Induction of Survivin Expression by Taxol (Paclitaxel) Is an Early Event, Which Is Independent of Taxol-mediated G2/M Arrest. J. Biol. Chem. 279: 15196-15203 [Abstract] [Full Text]  
• de Jonge, M. E., van den Bongard, H. J. G. D., Huitema, A. D. R., Mathot, R. A. A., Rosing, H., Baas, P., van Zandwijk, N., Beijnen, J. H., Schellens, J. H. M. (2004). Bayesian Pharmacokinetically Guided Dosing of Paclitaxel in Patients with Non-Small Cell Lung Cancer. Clin. Cancer Res. 10: 2237-2244 [Abstract] [Full Text]  
• Bani, M. R., Nicoletti, M. I., Alkharouf, N. W., Ghilardi, C., Petersen, D., Erba, E., Sausville, E. A., Liu, E. T., Giavazzi, R. (2004). Gene expression correlating with response to paclitaxel in ovarian carcinoma xenografts. Molecular Cancer Therapeutics 3: 111-121 [Abstract] [Full Text]  
• Itoh, Y., Sendo, T., Hirakawa, T., Goromaru, T., Takasaki, S., Yahata, H., Nakano, H., Oishi, R. (2004). Role of Sensory Nerve Peptides Rather than Mast Cell Histamine in Paclitaxel Hypersensitivity. Am. J. Respir. Crit. Care Med. 169: 113-119 [Abstract] [Full Text]  
• Yin, M.-J., Shao, L., Voehringer, D., Smeal, T., Jallal, B. (2003). The Serine/Threonine Kinase Nek6 Is Required for Cell Cycle Progression through Mitosis. J. Biol. Chem. 278: 52454-52460 [Abstract] [Full Text]  
• Moore, D. H., Donnelly, J., McGuire, W. P., Almadrones, L., Cella, D. F., Herzog, T. J., Waggoner, S. E. (2003). Limited Access Trial Using Amifostine for Protection Against Cisplatin- and Three-Hour Paclitaxel-Induced Neurotoxicity: A Phase II Study of the Gynecologic Oncology Group. JCO 21: 4207-4213 [Abstract] [Full Text]  
• Advani, R., Fisher, G. A., Lum, B. L., Jambalos, C., Cho, C. D., Cohen, M., Gollerkeri, A., Sikic, B. I. (2003). Phase I and Pharmacokinetic Study of BMS-188797, a New Taxane Analog, Administered on a Weekly Schedule in Patients with Advanced Malignancies. Clin. Cancer Res. 9: 5187-5194 [Abstract] [Full Text]  
• Sun, W., Stevenson, J. P., Gallagher, M. L., Vaughn, D., Hahn, S. M., Haller, D. G., Cohen, M., Kopit, J., Gallant, G., O'Dwyer, P. J. (2003). Phase I and Pharmacokinetic Trial of the Novel Taxane BMS-184476 Administered as a 1-Hour Intravenous Infusion in Combination with Cisplatin Every 21 Days. Clin. Cancer Res. 9: 5221-5227 [Abstract] [Full Text]  
• Rock, E., DeMichele, A. (2003). Nutritional Approaches to Late Toxicities of Adjuvant Chemotherapy in Breast Cancer Survivors. J. Nutr. 133: 3785S-3793 [Abstract] [Full Text]  
• Scheller, B., Speck, U., Schmitt, A., Bohm, M., Nickenig, G. (2003). Addition of paclitaxel to contrast media prevents restenosis after coronary stent implantation. J Am Coll Cardiol 42: 1415-1420 [Abstract] [Full Text]  
• Wolff, A. C., Donehower, R. C., Carducci, M. K., Carducci, M. A., Brahmer, J. R., Zabelina, Y., Bradley, M. O., Anthony, F. H., Swindell, C. S., Witman, P. A., Webb, N. L., Baker, S. D. (2003). Phase I Study of Docosahexaenoic Acid-Paclitaxel: a Taxane-Fatty Acid Conjugate with a Unique Pharmacology and Toxicity Profile. Clin. Cancer Res. 9: 3589-3597 [Abstract] [Full Text]  
• Scheller, B., Speck, U., Romeike, B., Schmitt, A., Sovak, M., Bohm, M., Stoll, H.-P. (2003). Contrast media as carriers for local drug delivery: Successful inhibition of neointimal proliferation in the porcine coronary stent model. Eur Heart J 24: 1462-1467 [Abstract] [Full Text]  
• Takimoto, C. H., Rowinsky, E. K. (2003). Dose-Intense Paclitaxel: Deja Vu All Over Again?. JCO 21: 2810-2814 [Full Text]  
• Garofalo, A., Naumova, E., Manenti, L., Ghilardi, C., Ghisleni, G., Caniatti, M., Colombo, T., Cherrington, J. M., Scanziani, E., Nicoletti, M. I., Giavazzi, R. (2003). The Combination of the Tyrosine Kinase Receptor Inhibitor SU6668 with Paclitaxel Affects Ascites Formation and Tumor Spread in Ovarian Carcinoma Xenografts Growing Orthotopically. Clin. Cancer Res. 9: 3476-3485 [Abstract] [Full Text]  
• Pearce, B. J., McKinsey, J. F. (2003). Current Status of Intravascular Stents as Delivery Devices to Prevent Restenosis. VASC ENDOVASCULAR SURG 37: 231-237 [Abstract]  
• Markman, M., Liu, P.Y., Wilczynski, S., Monk, B., Copeland, L. J., Alvarez, R. D., Jiang, C., Alberts, D. (2003). Phase III Randomized Trial of 12 Versus 3 Months of Maintenance Paclitaxel in Patients With Advanced Ovarian Cancer After Complete Response to Platinum and Paclitaxel-Based Chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group Trial. JCO 21: 2460-2465 [Abstract] [Full Text]  
• Kemper, E. M., van Zandbergen, A. E., Cleypool, C., Mos, H. A., Boogerd, W., Beijnen, J. H., van Tellingen, O. (2003). Increased Penetration of Paclitaxel into the Brain by Inhibition of P-Glycoprotein. Clin. Cancer Res. 9: 2849-2855 [Abstract] [Full Text]  
• Gunawardana, D. H., Basser, R. L., Davis, I. D., Cebon, J., Mitchell, P., Underhill, C., Kilpatrick, T. J., Reardon, K., Green, M. D., Bardy, P., Amor, P., Crump, D., Ng, S., Nation, R. L., Begley, C. G. (2003). A Phase I Study of Recombinant Human Leukemia Inhibitory Factor in Patients with Advanced Cancer. Clin. Cancer Res. 9: 2056-2065 [Abstract] [Full Text]  
• Lu, C., Komaki, R., Lee, J. S., Shin, D. M., Palmer, J. L., Coldman, B. J., Pisters, K. M., Kurie, J. M., Fossella, F. V., Glisson, B. S. (2003). A Phase I Study of Topotecan/Paclitaxel Alternating with Etoposide/Cisplatin and Thoracic Irradiation in Patients with Limited Small Cell Lung Cancer. Clin. Cancer Res. 9: 2085-2091 [Abstract] [Full Text]  
• Schmitt-Sody, M., Strieth, S., Krasnici, S., Sauer, B., Schulze, B., Teifel, M., Michaelis, U., Naujoks, K., Dellian, M. (2003). Neovascular Targeting Therapy: Paclitaxel Encapsulated in Cationic Liposomes Improves Antitumoral Efficacy. Clin. Cancer Res. 9: 2335-2341 [Abstract] [Full Text]  
• Sousa, J. E., Serruys, P. W., Costa, M. A. (2003). New Frontiers in Cardiology: Drug-Eluting Stents: Part II. Circulation 107: 2383-2389 [Full Text]  
• Park, S.-J., Shim, W. H., Ho, D. S., Raizner, A. E., Park, S.-W., Hong, M.-K., Lee, C. W., Choi, D., Jang, Y., Lam, R., Weissman, N. J., Mintz, G. S. (2003). A Paclitaxel-Eluting Stent for the Prevention of Coronary Restenosis. NEJM 348: 1537-1545 [Abstract] [Full Text]  
• Valero, V., Hortobagyi, G. N. (2003). Are Anthracycline-Taxane Regimens the New Standard of Care in the Treatment of Metastatic Breast Cancer?. JCO 21: 959-962 [Full Text]  
• Sledge, G. W., Neuberg, D., Bernardo, P., Ingle, J. N., Martino, S., Rowinsky, E. K., Wood, W. C. (2003). Phase III Trial of Doxorubicin, Paclitaxel, and the Combination of Doxorubicin and Paclitaxel as Front-Line Chemotherapy for Metastatic Breast Cancer: An Intergroup Trial (E1193). JCO 21: 588-592 [Abstract] [Full Text]  
• Minisini, A. M., Tosti, A., Sobrero, A. F., Mansutti, M., Piraccini, B. M., Sacco, C., Puglisi, F. (2003). Taxane-induced nail changes: incidence, clinical presentation and outcome. Ann Oncol 14: 333-337 [Abstract] [Full Text]  
• Boldt, S., Weidle, U. H., Kolch, W. (2002). The role of MAPK pathways in the action of chemotherapeutic drugs. Carcinogenesis 23: 1831-1838 [Abstract] [Full Text]  
• Goodin, S., Cunningham, R. (2002). 5-HT3-Receptor Antagonists for the Treatment of Nausea and Vomiting: A Reappraisal of Their Side-Effect Profile. The Oncologist 7: 424-436 [Abstract] [Full Text]  
• Kataoka, T., Grube, E., Honda, Y., Morino, Y., Hur, S.-H., Bonneau, H. N., Colombo, A., Di Mario, C., Guagliumi, G., Hauptmann, K. E., Pitney, M. R., Lansky, A. J., Stertzer, S. H., Yock, P. G., Fitzgerald, P. J., for the SCORE Investigators, (2002). 7-Hexanoyltaxol-Eluting Stent for Prevention of Neointimal Growth: An Intravascular Ultrasound Analysis From the Study to COmpare REstenosis rate between QueST and QuaDS-QP2 (SCORE). Circulation 106: 1788-1793 [Abstract] [Full Text]  
• Rowinsky, E. K. (2002). Taxane Analogues: Distinguishing Royal Robes from the "Emperor's New Clothes". Clin. Cancer Res. 8: 2759-2763 [Full Text]  
• Mukhopadhyay, T., Sasaki, J.-i., Ramesh, R., Roth, J. A. (2002). Mebendazole Elicits a Potent Antitumor Effect on Human Cancer Cell Lines Both in Vitro and in Vivo. Clin. Cancer Res. 8: 2963-2969 [Abstract] [Full Text]  
• Cassinelli, G., Lanzi, C., Supino, R., Pratesi, G., Zuco, V., Laccabue, D., Cuccuru, G., Bombardelli, E., Zunino, F. (2002). Cellular Bases of the Antitumor Activity of the Novel Taxane IDN 5109 (BAY59-8862) on Hormone-refractory Prostate Cancer. Clin. Cancer Res. 8: 2647-2654 [Abstract] [Full Text]  
• Broker, L. E., Huisman, C., Ferreira, C. G., Rodriguez, J. A., Kruyt, F. A. E., Giaccone, G. (2002). Late Activation of Apoptotic Pathways Plays a Negligible Role in Mediating the Cytotoxic Effects of Discodermolide and Epothilone B in Non-Small Cell Lung Cancer Cells. Cancer Res. 62: 4081-4088 [Abstract] [Full Text]  
• Gilbar, P., Ridge, A. (2002). Dexamethasone prophylaxis for paclitaxel hypersensitivity. J Oncol Pharm Pract 8: 81-87 [Abstract]  
• Dowlati, A., Robertson, K., Cooney, M., Petros, W. P., Stratford, M., Jesberger, J., Rafie, N., Overmoyer, B., Makkar, V., Stambler, B., Taylor, A., Waas, J., Lewin, J. S., McCrae, K. R., Remick, S. C. (2002). A Phase I Pharmacokinetic and Translational Study of the Novel Vascular Targeting Agent Combretastatin A-4 Phosphate on a Single-Dose Intravenous Schedule in Patients with Advanced Cancer. Cancer Res. 62: 3408-3416 [Abstract] [Full Text]  
• Ryan, D. P., Penson, R. T., Ahmed, S., Chabner, B. A., Lynch, T. J. Jr. (2002). Reality Testing in Cancer Treatment: The Phase I Trial of Endostatin. The Oncologist 7: 58-65 [Abstract] [Full Text]  
• Ibrahim, N. K., Desai, N., Legha, S., Soon-Shiong, P., Theriault, R. L., Rivera, E., Esmaeli, B., Ring, S. E., Bedikian, A., Hortobagyi, G. N., Ellerhorst, J. A. (2002). Phase I and Pharmacokinetic Study of ABI-007, a Cremophor-free, Protein-stabilized, Nanoparticle Formulation of Paclitaxel. Clin. Cancer Res. 8: 1038-1044 [Abstract] [Full Text]  
• Del Bufalo, D., Di Castro, V., Biroccio, A., Varmi, M., Salani, D., Rosano, L., Trisciuoglio, D., Spinella, F., Bagnato, A. (2002). Endothelin-1 Protects Ovarian Carcinoma Cells against Paclitaxel-Induced Apoptosis: Requirement for Akt Activation. Mol. Pharmacol. 61: 524-532 [Abstract] [Full Text]  
• Auzenne, E., Donato, N. J., Li, C., Leroux, E., Price, R. E., Farquhar, D., Klostergaard, J. (2002). Superior Therapeutic Profile of Poly-L-Glutamic Acid-Paclitaxel Copolymer Compared with Taxol in Xenogeneic Compartmental Models of Human Ovarian Carcinoma. Clin. Cancer Res. 8: 573-581 [Abstract] [Full Text]  
• Kottke, T. J., Blajeski, A. L., Meng, X. W., Svingen, P. A., Ruchaud, S., Mesner, P. W. Jr., Boerner, S. A., Samejima, K., Henriquez, N. V., Chilcote, T. J., Lord, J., Salmon, M., Earnshaw, W. C., Kaufmann, S. H. (2002). Lack of Correlation between Caspase Activation and Caspase Activity Assays in Paclitaxel-treated MCF-7 Breast Cancer Cells. J. Biol. Chem. 277: 804-815 [Abstract] [Full Text]  
• Yamaguchi, H., Paranawithana, S. R., Lee, M. W., Huang, Z., Bhalla, K. N., Wang, H.-G. (2002). Epothilone B Analogue (BMS-247550)-mediated Cytotoxicity through Induction of Bax Conformational Change in Human Breast Cancer Cells. Cancer Res. 62: 466-471 [Abstract] [Full Text]